Rxsight Inc RXST

$4.59 -0.21 (-4.38%)

Valuation

Market cap: 199,646,000
Revenue TTM: $134,480,000
Net income TTM: $-38,940,000
P/E (trailing): 0.00
P/E (forward): —
Profit margin: -28.96%
Debt to equity: 0.00

Trading

Volume: 1,196,900
Avg volume: 757,896
Day's range: $4.55 – $4.78
Shares out: 41,593,000
Stochastic %K: 7%
Beta: 1.21
Analysts: Hold
Price target: $7.57

Price

Company profile

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Industry: Medical Devices
Sector: Healthcare
Phone: 949 521 7830
Website: https://rxsight.com
Address: 100 Columbia, Aliso Viejo, United States

Latest news

2026-11-03T21:46:17.000Z · 10 hours ago

RxSight reports Q3 EPS (21c), consensus (29c)

2026-11-03T21:46:00.000Z · 10 hours ago

RxSight says nearly doubling sales force, completed organizational restructuring

Nov 3, 2026, 4:05 PM EST · 10 hours ago

RxSight, Inc. Reports Third Quarter 2026 Results

Oct 23, 2026, 8:00 PM EDT · 11 days ago

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Oct 20, 2026, 4:05 PM EDT · 14 days ago

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

Oct 19, 2026, 9:00 AM EDT · 15 days ago

RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation

Oct 16, 2026, 12:00 PM EDT · 18 days ago

K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world

2026-09-22T12:38:04.000Z · 6 weeks ago

RxSight price target lowered to $5.75 from $6.50 at Jefferies

2026-09-22T10:50:10.000Z · 6 weeks ago

RxSight price target lowered to $5.50 from $6.50 at BofA

Aug 26, 2026, 4:15 PM EDT · 2 months ago

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

2026-08-10T10:55:12.000Z · 2 months ago

RxSight price target lowered to $7 from $8 at Stifel

2026-08-06T12:50:12.000Z · 2 months ago

RxSight price target raised to $6.30 from $5.50 at UBS

2026-08-06T10:01:09.000Z · 2 months ago

RxSight says withdrawing guidance, will resume formal guidance in 2027

2026-08-05T21:15:53.000Z · 3 months ago

RxSight reports Q2 adjusted EPS (11c), consensus (19c)

Aug 5, 2026, 4:05 PM EDT · 3 months ago

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

2026-07-28T12:05:55.000Z · 3 months ago

RxSight resumed with a Neutral at UBS

2026-07-15T20:20:46.000Z · 3 months ago

RxSight Tarsus CEO Ron Kurtz to depart role, Aziz Mottiwala to succeed

TARS

Jul 15, 2026, 4:15 PM EDT · 3 months ago

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

Jul 8, 2026, 12:00 PM EDT · 3 months ago

Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

2026-07-07T19:50:31.000Z · 3 months ago

RxSight reports preliminary Q2 revenue $32M-$34M, consensus $32.07M

2026-07-07T19:50:11.000Z · 3 months ago

RxSight raises FY26 revenue view to $140M-$160M from $120M-$135M

2026-07-07T19:40:16.000Z · 3 months ago

RxSight price target lowered to $6.50 from $7.50 at Jefferies

Jul 7, 2026, 3:05 PM EDT · 3 months ago

The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors

2026-07-07T16:55:16.000Z · 3 months ago

RxSight price target lowered to $6.50 from $8 at BofA

2026-07-06T20:30:16.000Z · 4 months ago

Alcon, RxSight enter non-exclusive pact to develop adjustable PCIOLs

ALC

2026-07-06T20:25:22.000Z · 4 months ago

Alcon, RxSight announce collaboration to develop adjustable PCIOLs

ALC

Jul 6, 2026, 4:15 PM EDT · 4 months ago

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

Jul 6, 2026, 4:15 PM EDT · 4 months ago

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

Jul 2, 2026, 3:02 PM EDT · 4 months ago

Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

May 19, 2026, 4:10 PM EDT · 5 months ago

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum

2026-05-07T13:37:20.000Z · 6 months ago

RxSight price target lowered to $11 from $13 at Needham

2026-05-07T00:52:25.000Z · 6 months ago

RxSight reports Q1 adjusted EPS (19c), consensus (15c)

2026-05-07T00:51:25.000Z · 6 months ago

RxSight backs FY26 revenue view $120M-$135M, consensus $129.22M

May 6, 2026, 4:05 PM EDT · 6 months ago

RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook

Apr 29, 2026, 4:10 PM EDT · 6 months ago

RxSight, Inc. to Present at the Bank of America Healthcare Conference

Apr 22, 2026, 4:10 PM EDT · 6 months ago

RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6

Apr 8, 2026, 4:05 PM EDT · 6 months ago

RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026

Apr 2, 2026, 4:10 PM EDT · 7 months ago

RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference

Feb 11, 2026, 4:10 PM EST · 8 months ago

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Jan 11, 2026, 9:30 AM EST · 9 months ago

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

Jan 2, 2026, 4:05 PM EST · 10 months ago

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

Dec 22, 2025, 5:15 PM EST · 10 months ago

RxSight, Inc. Announces Chief Financial Officer Transition

Nov 20, 2025, 4:05 PM EST · 11 months ago

RxSight, Inc. to Present at the Piper Sandler Healthcare Conference

Nov 5, 2025, 4:05 PM EST · 12 months ago

RxSight, Inc. Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:05 PM EDT · 1 year ago

RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 16, 2025, 4:05 PM EDT · 1 year ago

RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting

Sep 22, 2025, 4:24 AM EDT · 1 year ago

RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST

Sep 16, 2025, 5:06 PM EDT · 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises RxSight, Inc. (NASDAQ: RXST) Investors to Contact the Firm Before September 22, 2025

Sep 14, 2025, 7:17 AM EDT · 1 year ago

RXST STOCK NEWS: RxSight, Inc. Investors Urged to Act by September 22 Court Deadline -- Contact BFA Law if You Suffered Losses

Sep 12, 2025, 8:18 AM EDT · 1 year ago

RXST SECURITIES NOTICE: Did RxSight, Inc. Mislead Investors? Contact BFA Law if You Lost Money on Your Investment

Sep 6, 2025, 7:18 AM EDT · 1 year ago

RXST LAWSUIT NOTICE: Lose Money on RxSight, Inc.? Contact BFA Law Prior to September 22 Legal Deadline (NASDAQ:RXST)

Aug 29, 2025, 7:07 AM EDT · 1 year ago

RXST SHAREHOLDERS: RxSight, Inc. Investors may have been Affected by Fraud – Contact BFA Law by September 22 Court Deadline (NASDAQ:RXST)

Aug 25, 2025, 4:05 PM EDT · 1 year ago

RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference

Stocktwits

EarningsInsider Nov 3, 10:31 PM

https://www.marketbeat.com/earnings/reports/2026-11-3-rxsight-inc-stock/ $RXST RxSight Earnings Transcript

0 replies

StocktwitsEarnings Nov 3, 9:09 PM

$RXST Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.21 down -425.00% YoY • Reported revenue of $24.59M down -18.95% YoY

0 replies

Invescent Nov 3, 4:22 PM

TOP 5 STOCKS THAT COULD SURGE AFTER HOURS NOVEMBER 3 Ranked by catalyst, float and short interest. 1. $RXST — 38.58M Float | 10.68% Short Q3 Earnings Today. Strong sales could trigger short covering. 2. $SCOR — 3.75M Float | 0.77% Short Q3 Earnings Today. Tiny float, strong results could spark a major move. 3. $SLDP — 197.98M Float | 15.43% Short Q3 Earnings Today. Battery partnership updates could attract buyers. 4. $RYAM — 61.05M Float | 7.60% Short Q3 Earnings Today. Strong profits and guidance could fuel a rally. 5. $CHCT — 26.76M Float | 2.92% Short Q3 Earnings Today. Better rental income could support a rebound.

0 replies